Skip to main content
Premium Trial:

Request an Annual Quote

EchelonDx, Oncocyte to Develop Software Supporting Commercial Diagnostics Expansion

NEW YORK – Healthcare informatics firm Echelon Diagnostics said Tuesday that it is collaborating with oncology diagnostic developer Oncocyte to develop analytical software that can scale to support the commercial expansion of Oncocyte's tests.

Based in Reno, Nevada, Echelon provides AI imaging and big data solutions supporting a range of molecular diagnostic technologies.

Irvine, California-based Oncocyte has built a pipeline of oncology diagnostic assays through acquisitions of various other companies and IP. Its first commercial offering, DetermaRx, is a 14-gene, RNA-based assay designed to identify patients with early-stage, non-small cell lung cancer who may benefit from adjuvant chemotherapy.

"EchelonDx was the right partner to help us build the software solution that allows us to scale and launch our proprietary tests worldwide in a manner that ensures … uniform and accurate testing," Oncocyte CSO Doug Ross said in a statement.

Financial terms of the agreement were not disclosed.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.